- Home
- AFCG vs LCTX Comparison
AFCG vs LCTX Comparison
Compare AFCG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- LCTX
- Stock Information
- Founded
- AFCG 2020
- LCTX 1990
- Country
- AFCG United States
- LCTX United States
- Employees
- AFCG N/A
- LCTX N/A
- Industry
- AFCG Real Estate Investment Trusts
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AFCG Real Estate
- LCTX Health Care
- Exchange
- AFCG Nasdaq
- LCTX Nasdaq
- Market Cap
- AFCG 113.0M
- LCTX 95.2M
- IPO Year
- AFCG 2021
- LCTX N/A
- Fundamental
- Price
- AFCG $5.50
- LCTX $0.48
- Analyst Decision
- AFCG Buy
- LCTX Strong Buy
- Analyst Count
- AFCG 7
- LCTX 5
- Target Price
- AFCG $11.00
- LCTX $4.20
- AVG Volume (30 Days)
- AFCG 144.3K
- LCTX 879.3K
- Earning Date
- AFCG 05-14-2025
- LCTX 05-13-2025
- Dividend Yield
- AFCG 23.93%
- LCTX N/A
- EPS Growth
- AFCG N/A
- LCTX N/A
- EPS
- AFCG 0.78
- LCTX N/A
- Revenue
- AFCG $41,494,025.00
- LCTX $9,499,000.00
- Revenue This Year
- AFCG N/A
- LCTX N/A
- Revenue Next Year
- AFCG $23.25
- LCTX $232.66
- P/E Ratio
- AFCG $8.33
- LCTX N/A
- Revenue Growth
- AFCG N/A
- LCTX 6.19
- 52 Week Low
- AFCG $4.34
- LCTX $0.37
- 52 Week High
- AFCG $10.88
- LCTX $1.40
- Technical
- Relative Strength Index (RSI)
- AFCG 48.49
- LCTX 52.76
- Support Level
- AFCG $5.27
- LCTX $0.37
- Resistance Level
- AFCG $5.87
- LCTX $0.51
- Average True Range (ATR)
- AFCG 0.24
- LCTX 0.04
- MACD
- AFCG 0.10
- LCTX 0.00
- Stochastic Oscillator
- AFCG 63.00
- LCTX 73.64
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.